Why study the epidemiology of asthma?
What sort of disease is asthma?
The causes of disease can be classified as inherited or acquired. Most diseases are influenced by both genetic and environmental factors but the source of risk that predominates ought to determine the research strategy most appropriate for unravelling the causes of the disease. Epidemiological studies indicate with one important exception that asthma is an acquired disease determined by the environment. The only clear exception to this is atopy, which most studies show to be a genetically determined risk factor for asthma, though the precise mode of inheritance is disputed. ' Beyond this there is little evidence for the inheritance of asthma. The largest and most sophisticated analysis so far to tackle this problem directly is a segregation analysis performed by Townley Epidemiologists distinguish between "efficacious" treatments, which are those that under ideal circumstances achieve what they are intended to, and "effective" treatments, which have a beneficial effect on the population as a whole.'4 Randomised controlled trials are used to assess what happens to subjects given a treatment under experimental conditions. The circumstances of treatment in such trials are tightly controlled and the subjects selected are often those most likely to comply with the regimen; they may even be those most likely to respond to the treatment. The randomised clinical trial has become the cornerstone of modern practice in assessing treatment; but there are aspects of management that cannot be assessed in this way, and the overall effect of management cannot be predicted from the results of randomised trials alone.
Firstly, randomised trials are rarely large or extensive enough to test whether a particular effect will be found in every group of subjects, or to exclude the possibility of a rare adverse effect. Secondly, the response to the drug will be influenced by the selection of patients to take the drug. A drug that has a favourable balance of therapeutic to unwanted effects in subjects selected, in the first instance, because they are believed to be the sort of patients who will benefit may show an adverse ratio ofbenefits to costs ifthe use of the drug extends to less ill patients or to those less suited to that treatment. A drug that is highly efficacious in a trial may well have disappointing or even adverse effects on the population as a whole.
The recent increase in mortality from asthma in several countries, including the United Kingdom,'5 and the wide variation in reported asthma mortality between areas and countries'617 inevitably raise questions concerning the overall effectiveness of modern treatment of asthma. The prescription of efficacious treatments for asthma has been rising steadily'8 while mortality from other "preventable" causes of death has been falling consistently, both in the United Kingdom and elsewhere. ' For over a decade now research on the aetiology of asthma has concentrated on the expensive investigation of pathogenetic hypotheses detached from any credible environmental explanation of the disease. It is perhaps time to take more seriously the evidence that asthma is in large measure an acquired condition. The mechanism of a disease is unlikely to be discovered before its cause, and at a time of apparently dwindling resources investment in the epidemiology of asthma should pay good dividends. 
